i-Tracker Risankizumab (Biosynex) is an automated assay intended for the quantitative measurement of Risankizumab (anti-IL23 agent) in human serum or plasma samples.
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds to the p19 subunit of human Interleukin (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a member of the IL-12 cytokine family and is implicated in a cluster of immune-mediated inflammatory diseases (IMIDs) that includes Pso, PsA, and inflammatory bowel disease (IBD – CD and UC).1
This Biosynex i-Tracker kit monitors Risankizumab, an interleukin-23 (IL-23) antagonist indicated in adults for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
References:
1. Krueger JG & al. IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Frontiers in Immunology. 2024 Apr 15:15:1331217.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
